Tekmira reports on protection against deadly Ebola virus

Tekmira Pharmaceuticals (TSX:TKM) has published a series of studies in The Lancet demonstrating the ability of an RNA-interference therapeutic using Tekmira’s SNALP lipid nanoparticle delivery technology to protect non-human primates from Ebola virus, a highly contagious and lethal human infectious disease. “These very striking data are the first demonstration that RNAi is efficacious in an [...]

Tekmira’s leading RNAi platform ready for prime time

As a global leader in the emerging field of RNA interference (RNAi), which holds the potential of revolutionizing medicine with new therapeutics, upstart Tekmira Pharmaceuticals (TSX:TKM) is at the precipice of confirming that the highly touted science works in humans. “We really are at the crux,” CEO Dr. Mark Murray says in an exclusive interview [...]